Nonoperating Income (Expense) in USD of Spero Therapeutics, Inc. from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Spero Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to Q3 2025.
  • Spero Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $534K, a 53.8% decline year-over-year.
  • Spero Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $3.27M, a 30.6% decline year-over-year.
  • Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $4.8M, a 22.2% increase from 2023.
  • Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $3.92M.
  • Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.22M, a 136% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Spero Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $3.27M $534K -$622K -53.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $3.89M $744K -$455K -37.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $4.35M $865K -$448K -34.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $4.8M $1.13M +$81K +7.74% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 $4.71M $1.16M +$216K +23% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $4.5M $1.2M +$223K +22.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $4.28M $1.31M +$352K +36.6% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $3.92M $1.05M +$199K +23.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 $3.72M $940K +$781K +491% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $2.94M $976K +$3.58M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$635K $961K +$3.58M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$4.22M $847K +$2.59M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$6.8M $159K +$156K +5200% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$6.96M -$2.6M -$2.57M -8573% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$4.39M -$2.62M -$2.6M -13010% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$1.79M -$1.74M -$1.95M -924% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $164K $3K -$81K -96.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $245K -$30K -$1.01M -103% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $1.25M -$20K +$417K +95.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $833K $211K -$686K -76.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $1.52M $84K -$184K -68.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $1.7M $975K +$473K +94.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.23M -$437K -$1.06M -170% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.29M $897K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 $268K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $502K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $624K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08

Spero Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $4.8M +$872K +22.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 $3.92M +$8.14M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 -$4.22M -$2.43M -136% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-13
2021 -$1.79M -$2.62M -314% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $833K -$1.46M -63.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 $2.29M +$1.15M +100% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 $1.14M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.